VocaVibe

Company Overview

Snapshot

Founded in June 2023 by Dr. Ariel Schiff and Dr. Alon Shapira, VocaVibe operates with 1–10 employees. The company has raised $1,000,000 across one funding round from one investor, eHealth Ventures. VocaVibe is currently in the clinical trial phase for its product, VocApp.

Business overview

VocaVibe develops non-invasive, AI-driven diagnostics for Parkinson's disease (PD) using vocal biomarkers. The company's core technology leverages artificial intelligence, including deep learning, voice and speech recognition, natural language processing, and machine learning, alongside acoustics sensing. VocaVibe aims to provide early and accurate diagnosis, continuous real-time monitoring of disease progression, and treatment efficacy. It serves the healthcare and life sciences markets, targeting providers, patients, and insurance companies, operating within the Digital Healthcare, Clinical Workflow, Medical Decision Support, Patient Remote Monitoring, and Digital Medical Diagnostics sectors.

Company Intelligence Q&A

When was VocaVibe founded?

VocaVibe was founded in June 2023.

Who are the founders of VocaVibe?

VocaVibe was founded by Dr. Ariel Schiff, who serves as CEO, and Dr. Alon Shapira, the CTO.

What is VocaVibe's primary focus?

VocaVibe focuses on AI-diagnosis and monitoring of Parkinson’s disease using voice, leveraging vocal biomarkers for early and accurate detection and continuous tracking of disease progression.

What is the current product stage for VocaVibe?

VocaVibe's product, VocApp, is currently in the clinical trial stage. The company is developing VocApp to provide non-invasive, AI-driven diagnostics for Parkinson's disease using vocal biomarkers.

Which investor participated in VocaVibe's funding round?

VocaVibe received funding from eHealth Ventures in June 2023.